103,016 Shares in Smith & Nephew plc (NYSE:SNN) Bought by Clearbridge Investments LLC

Clearbridge Investments LLC bought a new position in shares of Smith & Nephew plc (NYSE:SNN) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 103,016 shares of the medical equipment provider’s stock, valued at approximately $2,612,000.

Several other institutional investors have also recently made changes to their positions in SNN. CWM LLC raised its position in Smith & Nephew by 68.6% during the 4th quarter. CWM LLC now owns 954 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 388 shares in the last quarter. Argonautica Private Wealth Management Inc. lifted its position in Smith & Nephew by 4.5% during the 4th quarter. Argonautica Private Wealth Management Inc. now owns 10,362 shares of the medical equipment provider’s stock worth $283,000 after acquiring an additional 449 shares during the period. Highland Capital Management LLC lifted its position in Smith & Nephew by 1.8% during the 4th quarter. Highland Capital Management LLC now owns 24,915 shares of the medical equipment provider’s stock worth $680,000 after acquiring an additional 450 shares during the period. National Bank of Canada FI lifted its position in Smith & Nephew by 36.0% during the 4th quarter. National Bank of Canada FI now owns 1,967 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 521 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Smith & Nephew by 75.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,227 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 526 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew Trading Up 0.5 %

Shares of NYSE SNN traded up $0.15 during mid-day trading on Thursday, hitting $28.84. The company had a trading volume of 30,915 shares, compared to its average volume of 944,343. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44. Smith & Nephew plc has a 1-year low of $21.52 and a 1-year high of $31.31. The business’s 50-day simple moving average is $26.09 and its 200 day simple moving average is $26.31.

Wall Street Analysts Forecast Growth

SNN has been the subject of several analyst reports. UBS Group upgraded Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday, June 5th. StockNews.com cut Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Smith & Nephew in a research note on Wednesday. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.